This year, AbbVie has continually been a big spender in the TV ad drug stakes, and it’s showing no signs of slowing down. After launching two new Rinvoq commercials this summer, the Big Pharma is now ...
As we hit the middle of the year, AbbVie is comfortably back in the top TV drug ad spenders’ driving seat taking the top two spots in July with its immunology blockbuster duo Skyrizi and Rinvoq, ...
Skyrizi has knocked Dupixent off its pedestal and claimed the top spot for ad impressions by Rx and over-the-counter (OTC) brands in April. The treatment for Crohn’s disease, psoriasis and psoriatic ...
AbbVie’s Skyrizi took home the top spot for most pharma brand ad impressions in April, according to data released by iSpot.tv on Wednesday afternoon. The psoriasis treatment garnered an impressions ...
Although AbbVie's blockbuster treatment Humira (adalimumab) will see biosimilar competition this year, the company expects that Rinvoq (upadacitinib) and Skyrizi (risankizumab) will eventually see ...
The approval was based on data from two phase 3 induction studies, and one phase 3 maintenance study. The Food and Drug Administration (FDA) has approved Skyrizi ® (risankizumab-rzaa) for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback